
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

High blood pressure reprograms immune system
German scientists headed by Suphansa Sawamiphak from MDC Berlin have discovered in a zebrafish and mouse model of salt-induced hypertension that...

Pfizer-Seagen: Acquisition in the works
As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...

Oculis lists at Nasdaq through SPAC merger
Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...

Secarna Pharmaceuticals partners with SciNeuro Pharmaceuticals
According to the agreement, Secarna Pharmaceuticals GmbH & Co KG (Planegg, Germany) will identify and validate antisense locked nucleic acid...

Syngenta partners with Biotalys
Basel-headquartered Syngenta Crop Protection and Biotalys NV (Ghent) will collaborate to research, develop and commercialise protein-based biocontrol...

Dutch State to sell share capital of Intravacc BV
Two years after the establishment of the private company Intravacc BV (Bilthoven, The Netherlands), the sale of the former Netherlands Vaccine...